Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	829.25	660.12	443.31	267.59	195.99
Revenue Growth (YoY)	25.62%	48.91%	65.67%	36.53%	29.06%
Cost of Revenue	192.36	139.3	81.41	43.37	45.55
Gross Profit	636.89	520.81	361.9	224.23	150.45
Selling, General & Admin	149.18	143.53	50.32	45.74	77.25
Research & Development	76.36	66.61	35.67	34.24	140.8
Other Operating Expenses	73.77	43.15	0	0	0
Operating Expenses	299.32	253.28	86	79.97	218.06
Operating Income	337.57	267.53	275.9	144.26	-67.61
Interest Expense / Income	18.76	16.95	7.53	20.38	11.63
Other Expense / Income	-29.52	1.67	19.86	-5.43	-6.99
Pretax Income	348.33	248.92	248.52	129.3	-72.25
Income Tax	66.74	46.79	-154.19	0.22	-0.01
Net Income	281.59	202.13	402.71	129.09	-72.24
Net Income Growth	39.31%	-49.81%	211.97%	-	-
Shares Outstanding (Basic)	132	137	141	136	144
Shares Outstanding (Diluted)	134	141	147	141	144
Shares Change	-4.56%	-4.22%	3.77%	-1.99%	0.51%
EPS (Basic)	2.13	1.48	2.86	0.95	-0.50
EPS (Diluted)	2.10	1.44	2.74	0.91	-0.50
EPS Growth	45.83%	-47.45%	201.10%	-	-
Free Cash Flow	373.28	261.31	297.98	54.03	-89.46
Free Cash Flow Per Share	2.83	1.91	2.12	0.40	-0.62
Gross Margin	76.80%	78.90%	81.64%	83.79%	76.76%
Operating Margin	40.71%	40.53%	62.24%	53.91%	-34.50%
Profit Margin	33.96%	30.62%	90.84%	48.24%	-36.86%
Free Cash Flow Margin	45.01%	39.58%	67.22%	20.19%	-45.65%
Effective Tax Rate	19.16%	18.80%	-62.04%	0.17%	-
EBITDA	451.95	315.51	259.04	152.96	-56.56
EBITDA Margin	54.50%	47.80%	58.43%	57.16%	-28.86%
Depreciation & Amortization	84.86	49.64	3	3.28	4.07
EBIT	367.09	265.87	256.04	149.68	-60.62
EBIT Margin	44.27%	40.28%	57.76%	55.94%	-30.93%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).